Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A-Reference-Cited by-同舟云学术

Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A

Published:2022-07-08 Issue:6 Volume:28 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Wu Runhui¹^ORCID,Wang Xiaoling¹,Zhao Xielan²,Cheng Yanli³,Zhou Zeping⁴,Sun Jing⁵,Xu Ming⁶,Li Wenqian⁷,Xiao Jianwen⁸,Yang Fenge⁹,Chen Yun¹⁰,Xu Weiqun¹¹,Huang Jing¹²,Ma Chuanrong¹³,Gai Wenlin¹³,Xie Liangzhi¹³,Yang Renchi¹⁴

Affiliation:

1. Beijing Children's Hospital Capital Medical University Beijing People's Republic of China

2. Xiangya Hospital Central South University Hunan People's Republic of China

3. Shanxi Provincial Children's Hospital Shanxi People's Republic of China

4. The Second Affiliated Hospital of Kunming Medical University Yunnan People's Republic of China

5. Nanfang Hospital Affiliated to Southern Medical University Guangdong People's Republic of China

6. Chengdu Women's & Children's Central Hospital Sichuan People's Republic of China

7. Qinghai Provincial People's Hospital Qinghai People's Republic of China

8. The Affiliated Children's Hospital of Chongqing Medical University Chongqing People's Republic of China

9. Fujian Medical University Union Hospital Fujian People's Republic of China

10. Jinan Central Hospital Shandong People's Republic of China

11. The Affiliated Children's Hospital of Zhejiang Medical University Zhejiang People's Republic of China

12. The Affiliated Hospital of Guizhou Medical University Guangdong People's Republic of China

13. Beijing Engineering Research Center of Protein and Antibody Sinocelltech Ltd. Beijing People's Republic of China

14. State Key Laboratory of Experimental Hematology National Clinical Research Center for Hematological Disorders Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin People's Republic of China

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14622

Reference23 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. WFH Guidelines for the Management of Hemophilia, 3rd edition

3. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

4. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

5. Haemophilia care in China: Achievements in the past decade

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Report on the diagnosis and treatment of hemophilia in China (Version 2024);LabMed Discovery;2024-07

2. Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”;Advances in Therapy;2024-02-10

3. A Response to: Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”;Advances in Therapy;2024-02-10